Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Raw Materials (2023 - 2026)

Profound Medical has reported Raw Materials over the past 3 years, most recently at $3.0 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 50.61% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, up 50.61%, while the annual FY2025 figure was $3.0 million, 50.61% up from the prior year.
  • Raw Materials for Q4 2025 was $3.0 million at Profound Medical, up from $2.5 million in the prior quarter.
  • Over five years, Raw Materials peaked at $3.0 million in Q4 2025 and troughed at $2.0 million in Q4 2024.
  • A 3-year average of $2.4 million and a median of $2.4 million in 2023 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: dropped 16.46% in 2024 and later soared 50.61% in 2025.
  • Year by year, Raw Materials stood at $2.4 million in 2023, then fell by 16.46% to $2.0 million in 2024, then soared by 50.61% to $3.0 million in 2025.
  • Business Quant data shows Raw Materials for PROF at $3.0 million in Q4 2025, $2.5 million in Q3 2025, and $2.7 million in Q2 2025.